Download PDF
Open Access
CC BY 4.0 · Indian J Med Paediatr Oncol 2025; 46(06): 588-593
DOI: 10.1055/s-0045-1809301
Original Article

Mutation Analysis of Advanced Non-Small Cell Lung Cancer: A Retrospective Observational Study from South India

Authors

  • Sanudev Sadanandan Vadakke Puthiyottil 

    1   Department of Medical Oncology, Government Medical College, Kozhikode, Kerala, India

  • Arathi Edayattil

    1   Department of Medical Oncology, Government Medical College, Kozhikode, Kerala, India

  • Mohamed Jabir

    1   Department of Medical Oncology, Government Medical College, Kozhikode, Kerala, India

  • Jerin James 

    2   Government Medical College, Kozhikode, Kerala, India

  • Supriya N. K.

    3   Department of Pathology, Government Medical College, Kozhikode, Kerala, India

Funding None.
Further Information
Also available at
  Permissions and Reprints

Abstract

Introduction

Lung cancer is a leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) being the predominant type. Comprehensive genomic profiling plays a crucial role in identifying actionable mutations to guide personalized treatment strategies, especially in regions like India where late-stage diagnoses are common.

Objective

This retrospective observational study aimed to determine the prevalence of actionable mutations in patients with advanced NSCLC from a tertiary cancer care center in South India.

Materials and Methods

A retrospective observational study was conducted at the Department of Medical Oncology, Government Medical College, Kozhikode, South India. The study included 50 histologically confirmed patients with advanced NSCLC who underwent molecular testing between November 2022 and July 2024.

Results

Among the 50 patients, adenocarcinoma was the predominant histological subtype (70%), with TP53 and EGFR mutations found in 42 and 34%, respectively. Co-mutations, including TP53 + EGFR exon 19 deletions, were observed in 4% of cases. Low PD-L1 expression (<1%) was identified in 78% of patients, suggesting limited eligibility for single agent immunotherapy.

Conclusion

Comprehensive genomic profiling is largely inaccessible to most patients in India due to high costs, but targeted next-generation sequencing (NGS) panels offer a cost-effective way to optimize treatment. This study highlights the heterogeneity of mutations in NSCLC in South Indian patients and showcases the importance of targeted NGS panels in optimizing therapeutic strategies.

Keywords

non-small cell lung cancer - mutations - personalized treatment - immunotherapy - EGFR mutations

Patients' Consent

Written informed consents of patients were not taken as it is a retrospective observational study, and data were collected from hospital records.




Publication History

Article published online:
22 May 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India